This content is for healthcare professionals only. Please confirm that you are a healthcare professional.AcceptDecline
touchSATELLITE SYMPOSIUM: Advanced Breast Cancer
Length of activity: 60 minutes Approved for 1 AMA PRA Category 1 Credits™ Prof. Stephen Johnston, Prof. Nadia Harbeck and Prof. Mario Campone discuss patient selection, adverse event management and future directions for CDK4/6 inhibitors in the management of breast cancer.
THIS CONTENT IS AVAILABLE FOR FREE TO REGISTERED USERS You are not currently logged in. LOGIN or REGISTER to access this content
LOGIN or REGISTER to access this content
Immediate, and unrestricted free access to all resources
Earn AMA PRA Category 1 Credits™ for completing accredited activities
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Watch an internationally renowned faculty discuss the optimization of cyclin-dependent kinase (CDK)4/6 inhibitor treatment for patients with breast cancer. Prof. Stephen Johnston, Prof. Nadia Harbeck and Prof. Mario Campone discuss patient selection, adverse event management and future directions for CDK4/6 inhibitors in the management of breast cancer.
The information in this activity is intended for oncologists, nurses and other healthcare professionals involved in the treatment of patients with breast cancer.
This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the ESMO Breast Cancer Annual Congress in May 2019. (The live voting content is no longer active for this symposium.)
After watching this touchSATELLITE SYMPOSIUM, you should be able to:
Identify differentiating factors for the use of each CDK4/6 inhibitor in patients with HR+/HER2- advanced breast cancer, including adverse event profile, dosing schedule and patient factors, and apply this knowledge effectively to inform optimal treatment selection, treatment duration and sequencing on an individual patient basis in daily clinical practice.
Recognize the practical considerations for effective adverse event management with each of the three CDK4/6 inhibitors, including monitoring requirements and how to best manage adverse event prevention and treatment within the multidisciplinary team.
Recall emerging data from ongoing clinical trials investigating the use of CDK4/6 inhibitors in early HR+/HER2- breast cancer.
1 AMA PRA Category 1 Credits™ Date of original release: May 24, 2019 Date credits expire: May 24, 2020
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Yersal O, Barutcal S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412–424.
Hammond ME, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48–72.
Cortes J, et al. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treat Res. 2017;61:53–60.
Cardoso F, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;28:16–33.
Lobbezoo DJ, et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016;27;256–262.
Spring LM, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 2017;22:1039–1048.
Preusser M, et al. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary roundtable discussion. ESMO Open 2019;3:e000368.
Goetz MP et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–3646.
Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936
Hortobagyi GN, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541–1547.
Martin M, et al. Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC). Cancer Res. 2018;78 (Suppl):Abstract PD5-01.
Johnston S, et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor positive early breast cancer: PALLET Trial. J Clin Oncol. 2019;37:178–189.